secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001753926-23-001482
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical Q3 net loss $6.8M; adds NPM-115 for weight management
--------------------------------------------------------------------

- Net loss of $6.8M in Q3 2023 vs net income of $1.4M in Q3 2022, driven by prior-year bargain purchase gain.
- Cash and equivalents $26.2M at Sept 30, 2023; expected to fund operations into early 2025.
- Announced NPM-115 (high-dose exenatide implant) for chronic weight management in obese/overweight patients.
- FDA clinical hold on NPM-119 FIH study due to CMC requests; also planning FIH study in Australia.
- R&D expense $4.4M (+15% YoY); G&A expense $2.7M (+71% YoY) due to merger-related costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392623001482/0001753926-23-001482-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392623001482/g083854_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-23-001482

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer